Biomerica (NASDAQ:BMRA) issued its quarterly earnings data on Tuesday. The company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.01, Bloomberg Earnings reports. Biomerica had a negative net margin of 18.19% and a negative return on equity of 22.82%. The business had revenue of $1.61 million during the quarter, compared to analyst estimates of $1.48 million.
Shares of Biomerica (NASDAQ BMRA) traded down $0.44 on Wednesday, reaching $4.51. 206,500 shares of the company’s stock traded hands, compared to its average volume of 432,320. Biomerica has a twelve month low of $1.93 and a twelve month high of $9.32. The stock has a market capitalization of $42.22, a price-to-earnings ratio of -37.58 and a beta of -0.53.
Several brokerages have commented on BMRA. B. Riley began coverage on shares of Biomerica in a report on Thursday, January 4th. They issued a “buy” rating and a $7.50 price objective for the company. ValuEngine lowered shares of Biomerica from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
Biomerica Company Profile
Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.